Abstract: The present invention relates to novel variants of human BMP7 protein. The invention embodies vectors and host cells for the propagation of nucleic acid sequences encoding said proteins and the production thereof. Also disclosed are methods for the treatment of cancer, cartilage damage and degeneration, pain associated with osteoarthritis, or bone healing.
Type:
Grant
Filed:
April 20, 2018
Date of Patent:
October 11, 2022
Assignee:
ELI LILLY AND COMPANY
Inventors:
James David Pancook, Scott William Rowlinson, Louis Frank Stancato
Abstract: Present invention discloses particular peptide sequences of formula (I); (R1)(m)-Xaa1IXaa2T(Q)(p)(R2)(n) (I) (SEQ ID NO: 1); wherein R1, m, p, n, Xaa1, Xaa2, and R2 have particular meanings, or pharmaceutically or veterinary acceptable salts of these peptides that are effective in the prevention and/or treatment of mammal hair loss. Invention also relates to particular topical pharmaceutical, nutraceutical or veterinary compositions with the peptides of formula (I).
Type:
Grant
Filed:
March 31, 2017
Date of Patent:
October 11, 2022
Assignee:
VYTRUS BIOTECH, S.L.
Inventors:
Oscar Expósito Tarrés, Albert Jané Font, Sara Laplana Lasierra, Maria Mas Duarte, Tarik Ruiz Medina, Ana Gallego Palacios, Ana Belen Sabater Jara
Abstract: A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non-solvent impurities is not more than 0.3%. Up to 99% by volume of the insulin particles in the inhalable insulin have a particle size of less than 5 ?m, based on the total volume of the insulin particles. A high-efficiency method prepares high-purity inhalable insulin material. The yield rate for the high-efficiency method is 75 to 85% or more.
Type:
Grant
Filed:
August 28, 2019
Date of Patent:
September 20, 2022
Assignee:
AMPHASTAR PHARMACEUTCALS, INC.
Inventors:
Jeffrey Ding, Aili Bo, Mary Ziping Luo, Jack Yongfeng Zhang
Abstract: It has been discovered that the cyclic peptide EnnA inactivates the Hsp90 chaperone pathway, but without activating an extensive heat shock response and overexpression of anti-apoptotic proteins. Mechanistically distinct, EnnA inhibits Hsp90 and destabilize PDL-1 and IDO, two major immune checkpoints mediating tumor-induced immune suppression. The provided herein show that EnnA profoundly modulates the cytokine signature of cancer cells and promotes a cytokine profile that favors an immune attack on tumor cells. This translates into highly efficacious anti-tumor activity in vivo, which, when combined with a single dose of chemotherapy, completely reduced the tumor burden in experimental animals and instilled highly efficient immune memory against the primary tumor.
Type:
Grant
Filed:
November 5, 2018
Date of Patent:
September 20, 2022
Assignee:
AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
Type:
Grant
Filed:
January 21, 2020
Date of Patent:
September 6, 2022
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Stanley Richard Krystek, Jr., Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Juhi Juneja
Abstract: The present invention provides immune stimulating peptides (immunorhelins) capable of stimulating GnRH receptors when dosed to human patients or cells. These immunorhelins have utility in treating viral diseases and cancer.
Type:
Grant
Filed:
January 19, 2018
Date of Patent:
September 6, 2022
Assignee:
ISR IMMUNE SYSTEM REGULATION HOLDING AB
Inventors:
Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
Abstract: The present invention relates to a new peptide called Antisecretory Factor (AF) 17 which is an isolated recombinant and/or synthetically produced which has a t½ of at least 1.8 h. The peptide is e.g. useful for normalizing pathological fluid transport and/or inflammatory reactions in animals and in humans. AF-17 and pharmaceutical compositions of AF-17 can e.g. be used for treating and/or preventing TBI and/or secondary brain injuries associated with TBI, as well as for treating and/or preventing acquired brain injuries and to optimize cancer treatment.
Abstract: The inventors have determined that increasing the expression level or activity of FKBP-L polypeptide in a subject, which can be provided by expression of nucleic acids encoding FKBP-L or by providing FKBP-L polypeptides to a subject is advantageous for use in the treatment of obesity and obesity-related disorders. In particular increased expression or activity of FKBP-L polypeptide in a subject may be used to treat excessive weight gain (which can be characterised as obesity), glucose intolerance, diabetes and metabolic syndrome, which are closely linked to obesity and insulin resistance. FKBP-L can also be used as a biomarker for obesity and obesity-related disorders.
Type:
Grant
Filed:
October 18, 2017
Date of Patent:
July 5, 2022
Assignee:
Royal College of Surgeons in Ireland
Inventors:
Tracy Robson, David Grieve, Amy Short, Adrien Kissenpfennig, Marie Migaud, Rachel Bennett, Anita Yakkundi, Helen McCarthy
Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.
Type:
Grant
Filed:
August 24, 2016
Date of Patent:
June 7, 2022
Assignee:
Novo Nordisk A/S
Inventors:
Peter Madsen, Anthony Murray, Martin Muenzel, Claudia Ulrich Hjoerringgaard, Susanne Hostrup, Tine Glendorf, Mathias Norrman, Christian Fledelius
Abstract: Pharmaceutical compositions for treating, mitigating or preventing autoimmune diseases and associated conditions are described herein. Methods for fabricating the compositions and using them are also described.
Abstract: The present invention provides, among other things, improved therapeutic compositions comprising a C3 fusion protein and methods of making and using the same. In particular, the present invention provides improved methods for the treatment of spinal cord injury and other CNS trauma and/or facilitate axon growth or other tissue repair.
Type:
Grant
Filed:
May 30, 2018
Date of Patent:
May 10, 2022
Assignee:
BioAxone BioSciences, Inc.
Inventors:
Ricardo Borjas, Mark Fleming, Mei Huang, Mayur Jain, Tapan Sanghvi, Kumkum Saxena, Amaris Torres-Delgado, Ping Yin, Lisa McKerracher, Elizabeth Ryu
Abstract: The present invention provides a method of treating intracellular infections, in particular intracellular bacterial, fungal, and protozoal infections.
Type:
Grant
Filed:
January 19, 2018
Date of Patent:
April 19, 2022
Assignee:
ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL)
Inventors:
Ola Winqvist, Emma Lindh, Robert Wallin, Matt Gregory, Steven Moss
Abstract: Methods for modulating lysosome-mediated microautophagy of a lipid or protein substrate in a cell are provided herein. In certain embodiments, said methods may comprise increasing lysosome-mediated microautophagy by treating the cell with a microautophagy-enhancing agent which increases lysosomal association-dissociation events between lysosomes and the cellular lipid or protein substrate and/or increases lysosomal degradation capacity; or decreasing lysosome-mediated microautophagy by treating the cell with a microautophagy-reducing agent which reduces lysosomal association-dissociation events between lysosomes and the cellular lipid or protein substrate and/or decreases lysosomal degradation capacity; thereby modulating lysosome-mediated microautophagy of the lipid or protein substrate.
Abstract: Disclosed is an agent for inhibiting or reducing light sensitivity comprising a substance that inhibits or reduces ubiquitination, for example, an agent for inhibiting or reducing light sensitivity capable of protecting a retina, reducing retinal degeneration, reducing aging of a retina and/or reducing hyperesthesia. The present invention is suitable for use in amelioration or prevention of a symptom associated with light reception, such as age-related macular degeneration, retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease, cone-rod dystrophy, diabetic retinopathy, macular edema, retinal ischemia, photosensitive seizure, photosensitive epilepsy, psychiatric disorders, photic maculopathy, asthenopia, retinal dysfunction, sleep disorders, migraine and light-induced damage.
Abstract: [Problem] To provide a composition for hemostasis that can be applied uniformly to a bleeding site and exerts a high hemostatic effect. [Solution] Provided is a composition to be applied to the subject as a spray, wherein the composition is characterized in that the spray is for hemostasis, and the composition includes a self-assembling peptide, the self-assembling peptide gelling due to self-assembly when the composition is applied to the bleeding site of the subject, and the self-assembling peptide being included in the composition in a concentration having an improved hemostatic capacity in comparison to direct application.
Abstract: A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.
Abstract: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.
Type:
Grant
Filed:
February 20, 2009
Date of Patent:
March 1, 2022
Assignee:
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Inventors:
Erkki Ruoslahti, Tambet Teesalu, Kazuki Sugahara